Dr. Madaus brings more than 20 years of experience in the diagnostics and life science industries. He most recently served as President, Chairman and CEO of Millipore Corporation, recently acquired by Merck KGaA. Before joining Millipore, Dr. Madaus was President, CEO and head of North American Operations for Roche Diagnostics Corporation. Prior to this he served as Vice President of Business Development for Roche Molecular Diagnostics and General Manager of Boehringer Mannheim Canada. He also held a number of senior-level sales, marketing and product management positions with Boehringer Mannheim Corporation in both Germany and the US. Dr. Madaus is a director of the Massachusetts High Technology Council and serves on the Life Sciences Collaborative Leadership Council of the Massachusetts Technology Collaborative. He has a Doctor of Veterinary Medicine from the University of Munich, Germany and a Ph.D. in veterinary medicine from the Veterinary School of Hanover, Germany.

Dr. Duffy joined Quanterix in 2007 and leads the team of scientists developing its single molecule detection technology.  Dr. Duffy was previously at Surface Logix, where he was the Director of Pharmacomer Technology. There he oversaw the development of a novel chemical technology for optimizing the PK/PD of small molecules that resulted in two drug candidates currently in Phase II clinical trials. Prior to that, Dr. Duffy was at Gamera Biosciences where he was a co-inventor of a centrifugal microfluidic device called the LabCD that was acquired and commercialized by Tecan.  Dr. Duffy is an inventor on 12 U.S. patents and has more than 20 publications in the fields of surface chemistry, microfluidics, and bioanalysis.  Dr. Duffy was a postdoctoral research fellow in the Department of Chemistry and Chemical Biology at Harvard University. He was the first Sir Alan Wilson Research Fellow of Emmanuel College, University of Cambridge.  Dr. Duffy obtained his Ph.D. in physical chemistry from the Department of Chemistry at the University of Cambridge, and his B.A. and M.A. degrees in Natural Sciences from Selwyn College, University of Cambridge.

Mr. Fournier joined Quanterix in early 2008 and leads a team of engineers developing the company’s single molecule detection platform. Mr. Fournier was previously at Illumina Corporation (formerly Cyvera), where he most recently served as Senior Staff Engineer working on their novel encoded particle systems. While at Illumina, he was responsible for the integration of optical, mechanical and electrical systems related to the "Veracode" platform. Prior to Illumina, Mr. Fournier served as Principal Engineer at Cidra Corporation where he was instrumental in bringing innovative fiber Bragg grating optical systems to market. He was also part of the team that built the fiber optic sensor business that was subsequently sold to Weatherford International in 2001. Mr. Fournier also worked at Gerber Systems Corporation where he brought laser-based "thermal imaging" to market on their high resolution plotters. Early in his career, he was a member of the research team at Agfa, electronic pre-press division. Mr. Fournier earned his B.S. in Electrical Engineering and M.S. degree specializing in Electro-Optics from the University of Massachusetts-Lowell.

Dr. Hanlon joined Quanterix in 2008 to identify unmet market opportunities that would benefit from the Company’s technology platform.  Prior to Quanterix, Dr. Hanlon  led several external research collaborations at Cytyc to discover novel biomarkers of cervical neoplasia, as well as an internal team focused on marker validation and the development of diagnostic assays.  Dr. Hanlon was Director, R&D at VisEn Medical and Project Manager at Proteome, where he led a team of scientists developing protein-centric databases for comparative and functional genomic applications.  He also served as Director of Neuroscience at Oncogene Research Products where he developed a life science portfolio consisting of neurochemical and immunological products.   Dr. Hanlon received his Ph.D. from the University of Illinois, Urbana-Champaign and was a postdoctoral research fellow at Harvard University and the University of California, San Diego.  He obtained a B.S. degree in Biochemistry from Worcester Polytechnic Institute.

Dr. Wilson joined Quanterix in 2010 to lead the development of breakthrough diagnostic products using single molecule detection technology. Dr. Wilson brings 20 years of leadership experience in in-vitro diagnostics product development at Abbott Laboratories where he developed and commercialized over 20 new products across the major clinical diagnostic areas. His technical accomplishments include a groundbreaking product for hemoglobin A1c monitoring using novel capture and detection technologies (U.S. patent and $80MM in revenue). He also has extensive partnership experience including leading a successful companion diagnostic venture with Wyeth. Most recently, Dr. Wilson pioneered an entrepreneurial accelerated product development model partnering with smaller diagnostics firms that cut time-to-market by half and cost by two-thirds. He is lead author of over 25 articles and abstracts, inventor on two U.S. patents, and recipient of numerous awards, including three Chairman Awards and four Entrepreneurial Awards. Dr. Wilson received his Ph.D. in biophysical chemistry and his M.S. in chemistry from the University of Illinois/Chicago. He obtained his B.A. in chemistry from the University of South Florida.